1
|
Kingsbury E, Odatzoglou P, Peschard AL, Wong H, Elders R. Intracranial invasion of a mast cell tumour in a dog: A case report and review of the literature. Vet Med Sci 2024; 10:e1402. [PMID: 38450948 PMCID: PMC10918976 DOI: 10.1002/vms3.1402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 01/05/2024] [Accepted: 02/09/2024] [Indexed: 03/08/2024] Open
Abstract
An 11-year-old, female-neutered beagle was presented with a growing soft tissue mass arising within the deep tissues of the left cranial cervical region. At presentation, facial asymmetry was evident along with palpable lymphadenomegaly. Magnetic resonance imaging demonstrated a locally invasive cervical mass with intracranial invasion through focal osteolysis of the occipital bone. After antihistamine administration, cytology confirmed mast cell tumour (MCT) with metastasis to local lymph nodes and liver. The owner chose to pursue lomustine and prednisolone, which were dispensed, but, before home administration, prolonged seizures/status epilepticus occurred prompting euthanasia. Postmortem examination confirmed a high-grade MCT associated with, and infiltrating through, muscle, calvarium, dura mata, leptomeninges and the underlying brain. We present the clinical, imaging, and pathological findings of an unprecedented case of extracranial MCT tumour causing osteolysis of an imperforate flat bone (occipital bone) and intracranial invasion.
Collapse
Affiliation(s)
- Edward Kingsbury
- Department of Veterinary MedicineUniversity of CambridgeCambridgeCambridgeshireUK
| | - Petros Odatzoglou
- Department of Veterinary MedicineUniversity of CambridgeCambridgeCambridgeshireUK
| | - A. L. Peschard
- Department of Veterinary MedicineUniversity of CambridgeCambridgeCambridgeshireUK
| | - Hannah Wong
- Department of Veterinary MedicineUniversity of CambridgeCambridgeCambridgeshireUK
| | - Richard Elders
- Department of Veterinary MedicineUniversity of CambridgeCambridgeCambridgeshireUK
| |
Collapse
|
2
|
Zmorzynski S, Kimicka-Szajwaj A, Szajwaj A, Czerwik-Marcinkowska J, Wojcierowski J. Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment. Genes (Basel) 2024; 15:137. [PMID: 38275618 PMCID: PMC10815783 DOI: 10.3390/genes15010137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 01/12/2024] [Accepted: 01/20/2024] [Indexed: 01/27/2024] Open
Abstract
Mast cell tumors are a large group of diseases occurring in dogs, cats, mice, as well as in humans. Systemic mastocytosis (SM) is a disease involving the accumulation of mast cells in organs. KIT gene mutations are very often seen in abnormal mast cells. In SM, high KIT/CD117 expression is observed; however, there are usually no KIT gene mutations present. Mastocytoma (MCT)-a form of cutaneous neoplasm-is common in animals but quite rare in humans. KIT/CD117 receptor mutations were studied as the typical changes for human mastocytosis. In 80% of human cases, the KIT gene substitution p.D816H was present. In about 25% of MCTs, metastasis was observed. Changes in the gene expression of certain genes, such as overexpression of the DNAJ3A3 gene, promote metastasis. In contrast, the SNORD93 gene blocks the expression of metastasis genes. The panel of miR-21-5p, miR-379, and miR-885 has a good efficiency in discriminating healthy and MCT-affected dogs, as well as MCT-affected dogs with and without nodal metastasis. Further studies on the pathobiology of mast cells can lead to clinical improvements, such as better MCT diagnosis and treatment. Our paper reviews studies on the topic of mast cells, which have been carried out over the past few years.
Collapse
|
3
|
Treggiari E, Valenti P, Porcellato I, Maresca G, Romanelli G. Retrospective analysis of outcome and prognostic factors of subcutaneous mast cell tumours in dogs undergoing surgery with or without adjuvant treatment. Vet Comp Oncol 2023; 21:437-446. [PMID: 37121954 DOI: 10.1111/vco.12902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2022] [Revised: 04/02/2023] [Accepted: 04/18/2023] [Indexed: 05/02/2023]
Abstract
Subcutaneous mast cell tumours (SC MCTs) can display a different biological behaviour in dogs when compared to their cutaneous counterpart. There is a paucity of information with regards to the outcome of dogs with SC MCTs treated with surgery and/or receiving adjuvant chemotherapy. The aim of this study was to retrospectively review the outcome of dogs with surgically excised SC MCTs undergoing adjuvant treatment or not. A secondary aim was to assess prognostic factors in the same group. Fifty-two cases were included. Recurrence rate was 15% and 63% of evaluated lymph nodes were consistent with early or overt metastasis. Median survival time (range 83-1357 days) and median time to progression (range 14-1357 days) were not reached. Factors predictive of shorter overall survival time included increasing age (HR 1.29, 95% CI 1.06-1.55, p = .0092), presence of clinical signs at presentation (HR 10.44, 95% CI 2.69-40.52, p = .0007), mitotic count >4 (HR 8.69, 95% CI 2.55-29.55, p = 0.0005), presence of multinucleation (HR 4.21, 95% CI 1.35-13.18, p = .0135), use of neoadjuvant and adjuvant chemotherapy (HR 7.16, 95% CI 1.26-40.73, p = .0266). The same factors, together with increasing tumour dimensions, were predictive for shorter progression-free survival (PFS), including increasing age (p = .0012), presence of clinical signs at presentation (p = .0045), increasing tumour dimensions (p = .0004), MC > 4 (p = .0004), presence of multinucleation (p = .0282), use of neoadjuvant and adjuvant chemotherapy (p = .0485). No variables remained significant for overall survival using multivariate analysis. There was a longer survival in cases where chemotherapy was not required (HR 0.14, 95% CI 0.03-0.68, p = .0148), and this variable remained significant for PFS on multivariate analysis (HR 0.13, 95% CI 0.02-0.76, p = .02). In conclusion, our study suggests that dogs with SC MCTs, in the absence of negative prognostic factors, may have a prolonged survival when treated with surgery alone. Further studies are needed to clarify the role of adjuvant treatment for biologically aggressive SC MCTs in dogs.
Collapse
Affiliation(s)
- E Treggiari
- Oncology Service, Centro Specialistico Veterinario, Milan, Italy
| | - P Valenti
- Oncology Service, Clinica Veterinaria Malpensa AniCura, Samarate, Italy
- Oncology Service, Ospedale Veterinario I Portoni Rossi AniCura, Zola Predosa, Italy
| | - I Porcellato
- Pathology Service, University of Perugia, School of Veterinary Medicine, Perugia, Italy
| | - G Maresca
- Oncology Service, Centro Specialistico Veterinario, Milan, Italy
| | - G Romanelli
- Oncology Service, Centro Specialistico Veterinario, Milan, Italy
| |
Collapse
|
4
|
Burge R, Woolard KD, Willcox JL, Rebhun RB, Burton JH, Al-Nadaf S, Skorupski KA. High-Grade, Stage 2 Mast Cell Tumors: Outcome in Dogs With Local and Systemic Therapy. J Am Anim Hosp Assoc 2023; 59:167-176. [PMID: 37432790 DOI: 10.5326/jaaha-ms-7319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/21/2023] [Indexed: 07/13/2023]
Abstract
Canine mast cell tumors (MCTs) have highly variable clinical behavior, and predicting outcomes in individual dogs remains challenging. Many studies combine dogs with varying tumor grades, clinical stage, or treatments, confounding those results. The purpose of this retrospective study was to determine outcome and prognostic factors in a specific subset of dogs with high-grade, stage 2, cutaneous MCTs treated with adequate local control via surgery with or without radiation therapy and adjuvant cytotoxic chemotherapy. Seventeen dogs met the inclusion criteria, and the median survival time was 259 days. Development of local recurrence, tumor location, and presence of ulceration were all associated with shorter survival times. Tumor size, mitotic count, chemotherapy protocol, lymph node classification, and radiation therapy were not significantly associated with outcome. In this study, a specific population of dogs characterized by high-grade MCTs with local lymph node metastasis who received aggressive local and systemic therapy had a median survival of about 8.5 mo. Dogs with ulcerated tumors, recurrent tumors, or tumors located on the head had a worse outcome despite aggressive therapy. These results may serve as a basis of comparison for future research exploring alternative treatment combinations in this specific population of dogs.
Collapse
Affiliation(s)
- Rhonda Burge
- From the Department of Veterinary Clinical Sciences (R.B.), College of Veterinary Medicine, The Ohio State University, Columbus, Ohio
| | - Kevin D Woolard
- Department of Pathology, Microbiology, and Immunology (K.D.W.), School of Veterinary Medicine, University of California, Davis, California
| | - Jennifer L Willcox
- Department of Surgical and Radiological Sciences (J.L.W., R.B.R., S.A.-N., K.A.S.), School of Veterinary Medicine, University of California, Davis, California
| | - Robert B Rebhun
- Department of Surgical and Radiological Sciences (J.L.W., R.B.R., S.A.-N., K.A.S.), School of Veterinary Medicine, University of California, Davis, California
| | - Jenna H Burton
- Clinical Sciences Department, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado (J.H.B.)
| | - Sami Al-Nadaf
- Department of Surgical and Radiological Sciences (J.L.W., R.B.R., S.A.-N., K.A.S.), School of Veterinary Medicine, University of California, Davis, California
| | - Katherine A Skorupski
- Department of Surgical and Radiological Sciences (J.L.W., R.B.R., S.A.-N., K.A.S.), School of Veterinary Medicine, University of California, Davis, California
| |
Collapse
|
5
|
Canine Apocrine Gland Anal Sac Adenocarcinoma: A Review. Top Companion Anim Med 2022; 50:100682. [PMID: 35792243 DOI: 10.1016/j.tcam.2022.100682] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 06/20/2022] [Accepted: 06/28/2022] [Indexed: 11/21/2022]
Abstract
Apocrine gland anal sac adenocarcinoma (AGASAC) is a relatively uncommon tumor in the dog and comprises approximately 17% of perianal malignancies; however, it is one of the most common causes of paraneoplastic hypercalcemia. Clinical signs in affected dogs most commonly are associated with mechanical obstruction caused by the primary tumor or enlarged regional metastatic lymph nodes and the effects of paraneoplastic hypercalcemia when present. Surgical excision of the primary tumor and metastasectomy of affected locoregional lymph nodes is the preferred initial treatment option for most dogs, although radiation therapy and adjuvant chemotherapy are commonly incorporated into multi-modality treatment plans. A significant role for the use of adjuvant chemotherapy has not been clearly demonstrated. Prolonged survival times are possible, especially for dogs with smaller primary tumors and for dogs that undergo further treatments for recurrent disease. In this article, we review the clinical signs, diagnosis, staging, treatment, and prognosis of AGASAC in the dog.
Collapse
|
6
|
Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study. Vet Sci 2022; 9:vetsci9060277. [PMID: 35737330 PMCID: PMC9227510 DOI: 10.3390/vetsci9060277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Revised: 05/30/2022] [Accepted: 06/03/2022] [Indexed: 11/30/2022] Open
Abstract
Glucocorticoid administration is a common clinical practice that attempts to decrease the inflammation associated with and improve the resectability of canine mast cell tumors (MCTs). However, the impact of neoadjuvant glucocorticoids on the histological features and proliferation indices of canine MCTs is unknown. The objective of this study was to evaluate changes in tumor grade, mitotic count, Ki67, AgNOR, and AgNORxKi67 scores following short-course anti-inflammatory neoadjuvant prednisone in canine patients with MCTs. This was a prospective single-arm pilot study. Client-owned dogs with treatment-naïve cytologically confirmed MCTs were enrolled. Patients underwent an initial incisional biopsy followed by a 10–14-day course of anti-inflammatory prednisone and surgical resection. All histological samples were randomized, masked, and evaluated by a single pathologist. Unstained paired pre- and post-treatment samples were submitted to a commercial laboratory for Ki67 and AgNOR immunohistochemical analysis. There were 11 dogs enrolled with 11 tumors. There were no statistical differences between the pre- and post-treatment histological parameters of mitotic index, Ki67, AgNOR, or Ki67xAgNOR. There were no clinically significant alterations between pre-treatment and post-treatment in the assignment of tumor grades. A short course of anti-inflammatory prednisone does not appear to alter the histological parameters that affect grade determination or significantly alter the proliferation indices in canine MCTs.
Collapse
|
7
|
Fejös C, Troedson K, Ignatenko N, Zablotski Y, Hirschberger J. Extensive staging has no prognostic value in dogs with low-risk mast cell tumours. Vet Comp Oncol 2021; 20:265-275. [PMID: 34564910 DOI: 10.1111/vco.12773] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 09/16/2021] [Accepted: 09/24/2021] [Indexed: 12/16/2022]
Abstract
In canine mast cell tumours (MCTs), distant metastasis (DM) occurs infrequently. However, high-risk MCTs or tumours with certain negative prognostic factors (NPFs) are those more prone to develop metastatic disease. Accordingly, a thorough workup might not be necessary for MCTs lacking NPFs. The objective of this study was to evaluate the rate of DM and, therefore, the benefit of extensive staging in dogs presenting with and without NPFs. Furthermore, the association between the selected NPFs and DM was assessed, and factors that may have influenced outcome were evaluated. Dogs presenting with at least one NPF (Patnaik III/Kiupel high-grade, LN metastasis, rapid growth, ulceration, recurrence, high-risk location) were defined as high-risk and without as low-risk MCTs. Ninety-nine dogs were included, with 49% of MCTs in the high-risk and 51% in the low-risk group. All seven dogs with DM were identified in the high-risk group; 43% were Patnaik III/Kiupel high-grade tumours. The median survival time (MST) for this subgroup was 84 days. Patnaik III/Kiupel high-grade and rapid growth were NPFs significantly associated with DM at staging. Furthermore, a significant difference (p < .001) in MST was demonstrated between the high-risk and low-risk groups (899 days vs. not reached). NPFs significantly associated with outcome were rapid growth, presence of DM at staging, and surgical tumour excision. These results indicate that extensive staging in the absence of NPFs does not seem to be beneficial. On the other hand, by using the selected NPFs, a subset of MCTs prone to DM can be identified.
Collapse
Affiliation(s)
- Csilla Fejös
- Clinic of Small Animal Medicine, Faculty of Veterinary Medicine, Ludwig-Maximilian University, Munich, Germany
| | - Karin Troedson
- Clinic of Small Animal Medicine, Faculty of Veterinary Medicine, Ludwig-Maximilian University, Munich, Germany
| | - Nataliia Ignatenko
- Clinic of Small Animal Medicine, Faculty of Veterinary Medicine, Ludwig-Maximilian University, Munich, Germany
| | - Yury Zablotski
- Clinic of Small Animal Medicine, Faculty of Veterinary Medicine, Ludwig-Maximilian University, Munich, Germany
| | - Johannes Hirschberger
- Clinic of Small Animal Medicine, Faculty of Veterinary Medicine, Ludwig-Maximilian University, Munich, Germany
| |
Collapse
|
8
|
Abrams BE, Putterman AB, Ruple A, Wavreille V, Selmic LE. Variability in tumor margin reporting for soft tissue sarcoma and cutaneous mast cell tumors in dogs: A systematic review. Vet Surg 2020; 50:259-272. [DOI: 10.1111/vsu.13539] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2020] [Revised: 10/01/2020] [Accepted: 10/17/2020] [Indexed: 12/16/2022]
Affiliation(s)
- Brittany E. Abrams
- Department of Veterinary Clinical Sciences College of Veterinary Medicine, The Ohio State University Columbus Ohio
| | - Allison B. Putterman
- Department of Veterinary Clinical Medicine College of Veterinary Medicine, University of Illinois at Urbana‐Champaign Urbana Illinois
| | - Audrey Ruple
- Department of Comparative Pathobiology College of Veterinary Medicine, Purdue University West Lafayette, Indiana
| | - Vincent Wavreille
- Department of Veterinary Clinical Sciences College of Veterinary Medicine, The Ohio State University Columbus Ohio
| | - Laura E. Selmic
- Department of Veterinary Clinical Sciences College of Veterinary Medicine, The Ohio State University Columbus Ohio
| |
Collapse
|
9
|
Ferrari R. Response to Letter to the Editor. Vet Comp Oncol 2019; 17:209-210. [DOI: 10.1111/vco.12467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Roberta Ferrari
- Dipartimento di Medicina VeterinariaUniversità degli Studi di Milano Milan Italy
| |
Collapse
|
10
|
Reynolds BD, Thomson MJ, O'Connell K, Morgan EJ, Gummow B. Patient and tumour factors influencing canine mast cell tumour histological grade and mitotic index. Vet Comp Oncol 2019; 17:338-344. [PMID: 30891882 DOI: 10.1111/vco.12477] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2018] [Revised: 02/24/2019] [Accepted: 03/11/2019] [Indexed: 12/17/2022]
Abstract
The aim of this study was to identify patient and tumour factors most frequently associated with high histological grades of canine mast cell tumours (MCTs). Search criteria in a shared database of multiple Animal Referral Hospital locations within Australia generated 400 canine MCTs in 286 patients. Patient and tumour data were extrapolated and the association between a tumour being histologically high grade and patient and tumour factors, including: patient breed, patient gender and neuter status, patient age at MCT excision, tumour location and tumour size was assessed using univariate analysis. The study consisted of 90 (21.9%) tumours meeting histological high-grade criteria. Shar peis were the most likely breed to have high grade MCTs, whereas the Pug and the Golden Retriever were the least likely breeds to develop high-grade MCTs. No significant difference in risks could be established between the age at which the tumour was excised, or the gender and neuter status of patients. MCTs of the inguinal region were the most likely single location to be high grade. Tumour size did not influence the likelihood of a tumour being high grade or low grade. The results of this study suggest that patient and tumour factors may play a role in the histological grades of canine MCTs.
Collapse
Affiliation(s)
- Benjamin D Reynolds
- Department of Oncology, Animal Referral Hospital Brisbane, Brisbane, Queensland, Australia
| | - Maurine J Thomson
- Department of Oncology, Animal Referral Hospital Brisbane, Brisbane, Queensland, Australia
| | - Kathleen O'Connell
- Department of Oncology, Animal Referral Hospital Brisbane, Brisbane, Queensland, Australia
| | - Elizabeth J Morgan
- Department of Oncology, Animal Referral Hospital Brisbane, Brisbane, Queensland, Australia
| | - Bruce Gummow
- Discipline of Veterinary Sciences, College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, Queensland, Australia
| |
Collapse
|
11
|
Schulman FY. The prognostic significance of microscopic lymph node metastasis of Patnaik grade I and II/Kiupel low‐grade MCTs has not been demonstrated. Vet Comp Oncol 2019; 17:208. [DOI: 10.1111/vco.12463] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2019] [Accepted: 01/31/2019] [Indexed: 01/01/2023]
|
12
|
Ferrari R, Marconato L, Buracco P, Boracchi P, Giudice C, Iussich S, Grieco V, Chiti LE, Favretto E, Stefanello D. The impact of extirpation of non-palpable/normal-sized regional lymph nodes on staging of canine cutaneous mast cell tumours: A multicentric retrospective study. Vet Comp Oncol 2018; 16:505-510. [DOI: 10.1111/vco.12408] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Revised: 05/02/2018] [Accepted: 05/04/2018] [Indexed: 12/22/2022]
Affiliation(s)
- R. Ferrari
- Dipartimento di Medicina Veterinaria; Università degli Studi di Milano; Milano Italy
| | - L. Marconato
- Centro Oncologico Veterinario; Sasso Marconi Italy
| | - P. Buracco
- Dipartimento di Scienze Veterinarie; Università degli Studi di Torino; Torino Italy
| | - P. Boracchi
- Dipartimento di Scienze Cliniche e di Comunità; Università degli Studi di Milano; Milano Italy
| | - C. Giudice
- Dipartimento di Medicina Veterinaria; Università degli Studi di Milano; Milano Italy
| | - S. Iussich
- Dipartimento di Scienze Veterinarie; Università degli Studi di Torino; Torino Italy
| | - V. Grieco
- Dipartimento di Medicina Veterinaria; Università degli Studi di Milano; Milano Italy
| | - L. E. Chiti
- Dipartimento di Medicina Veterinaria; Università degli Studi di Milano; Milano Italy
| | - E. Favretto
- Dipartimento di Scienze Veterinarie; Università degli Studi di Torino; Torino Italy
| | - D. Stefanello
- Dipartimento di Medicina Veterinaria; Università degli Studi di Milano; Milano Italy
| |
Collapse
|
13
|
Horta RS, Lavalle GE, Monteiro LN, Souza MCC, Cassali GD, Araújo RB. Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features. Vet Pathol 2018; 55:212-223. [DOI: 10.1177/0300985817747325] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Mast cell tumor (MCT) is a frequent cutaneous neoplasm in dogs that is heterogeneous in clinical presentation and biological behavior, with a variable potential for recurrence and metastasis. Accurate prediction of clinical outcomes has been challenging. The study objective was to develop a system for classification of canine MCT according to the mortality risk based on individual assessment of clinical, histologic, immunohistochemical, and molecular features. The study included 149 dogs with a histologic diagnosis of cutaneous or subcutaneous MCT. By univariate analysis, MCT metastasis and related death was significantly associated with clinical stage ( P < .0001, rP = –0.610), history of tumor recurrence ( P < .0001, rP = –0.550), Patnaik ( P < .0001, rP = –0.380) and Kiupel grades ( P < .0001, rP = –0.500), predominant organization of neoplastic cells ( P < .0001, rP = –0.452), mitotic count ( P < .0001, rP = –0.325), Ki-67 labeling index ( P < .0001, rP = –0.414), KITr pattern ( P = .02, rP = 0.207), and c-KIT mutational status ( P < .0001, rP = –0.356). By multivariate analysis with Cox proportional hazard model, only 2 features were independent predictors of overall survival: an amendment of the World Health Organization clinical staging system (hazard ratio [95% CI]: 1.824 [1.210-4.481]; P = .01) and a history of tumor recurrence (hazard ratio [95% CI]: 9.250 [2.158-23.268]; P < .001]. From these results, we propose an amendment of the WHO staging system, a method of risk analysis, and a suggested approach to clinical and laboratory evaluation of dogs with cutaneous MCT.
Collapse
Affiliation(s)
| | - Gleidice E. Lavalle
- Department of Veterinary Clinics and Surgery, Veterinary School, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| | - Lidianne N. Monteiro
- Laboratory of Comparative Pathology, Biological Science Institute, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil
| | | | - Geovanni D. Cassali
- Laboratory of Comparative Pathology, Biological Science Institute, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil
| | - Roberto B. Araújo
- Department of Veterinary Clinics and Surgery, Veterinary School, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
| |
Collapse
|
14
|
Krick EL, Kiupel M, Durham AC, Thaiwong T, Brown DC, Sorenmo KU. Investigating Associations Between Proliferation Indices, C-kit, and Lymph Node Stage in Canine Mast Cell Tumors. J Am Anim Hosp Assoc 2017; 53:258-264. [DOI: 10.5326/jaaha-ms-6265] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
ABSTRACT
Previous studies have evaluated cellular proliferation indices, KIT expression, and c-kit mutations to predict the clinical behavior of canine mast cell tumors (MCTs). The study purpose was to retrospectively compare mitotic index, argyrophilic nucleolar organizer regions (AgNORs)/nucleus, Ki-67 index, KIT labeling pattern, and internal tandem duplication mutations in c-KIT between stage I and stage II grade II MCTs. Medical records and tumor biopsy samples from dogs with Grade II MCTs with cytological or histopathological regional lymph node evaluation were included. Signalment, tumor location and stage, and presence of a recurrent versus de novo tumor were recorded. Mitotic index, AgNORs/nucleus, Ki-67, KIT staining pattern, and internal tandem duplication mutations in exon 11 of c-KIT were evaluated. Sixty-six tumors (51 stage I; 15 stage II) were included. Only AgNORs/nucleus and recurrent tumors were significantly associated with stage (odds ratio 2.8, 95% confidence interval [CI] 1.0–8.0, P = .049; odds ratio 8.8, 95% CI 1.1–69.5; P = .039). Receiver-operator characteristic analysis showed that the sensitivity and specificity of AgNORs/cell ≥ 1.87 were 93.3% and 27.4%, respectively, (area under the curve: 0.65) for predicting stage. Recurrent tumors and higher AgNORs/nucleus are associated with stage II grade II MCTs; however, an AgNOR cutoff value that reliably predicts lymph node metastasis was not determined.
Collapse
Affiliation(s)
- Erika Lauren Krick
- From the School of Veterinary Medicine (E.L.K.), Department of Pathobiology (A.C.D.), and Department of Clinical Studies (D.C.B., K.U.S.), Veterinary Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Pathobiology and Diagnostic Investigations, Diagnostic Center for Population and Animal Health (M.K.), and the Comparative Medicine
| | - Matti Kiupel
- From the School of Veterinary Medicine (E.L.K.), Department of Pathobiology (A.C.D.), and Department of Clinical Studies (D.C.B., K.U.S.), Veterinary Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Pathobiology and Diagnostic Investigations, Diagnostic Center for Population and Animal Health (M.K.), and the Comparative Medicine
| | - Amy C. Durham
- From the School of Veterinary Medicine (E.L.K.), Department of Pathobiology (A.C.D.), and Department of Clinical Studies (D.C.B., K.U.S.), Veterinary Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Pathobiology and Diagnostic Investigations, Diagnostic Center for Population and Animal Health (M.K.), and the Comparative Medicine
| | - Tuddow Thaiwong
- From the School of Veterinary Medicine (E.L.K.), Department of Pathobiology (A.C.D.), and Department of Clinical Studies (D.C.B., K.U.S.), Veterinary Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Pathobiology and Diagnostic Investigations, Diagnostic Center for Population and Animal Health (M.K.), and the Comparative Medicine
| | - Dorothy C. Brown
- From the School of Veterinary Medicine (E.L.K.), Department of Pathobiology (A.C.D.), and Department of Clinical Studies (D.C.B., K.U.S.), Veterinary Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Pathobiology and Diagnostic Investigations, Diagnostic Center for Population and Animal Health (M.K.), and the Comparative Medicine
| | - Karin U. Sorenmo
- From the School of Veterinary Medicine (E.L.K.), Department of Pathobiology (A.C.D.), and Department of Clinical Studies (D.C.B., K.U.S.), Veterinary Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Pathobiology and Diagnostic Investigations, Diagnostic Center for Population and Animal Health (M.K.), and the Comparative Medicine
| |
Collapse
|
15
|
Mutz ML, Boudreaux BB, Royal A, Merchant S, Pucheu-Haston C, Griffith EH, Gieger TL. Cytologic comparison of the percentage of mast cells in lymph node aspirate samples from clinically normal dogs versus dogs with allergic dermatologic disease and dogs with cutaneous mast cell tumors. J Am Vet Med Assoc 2017; 251:421-428. [DOI: 10.2460/javma.251.4.421] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
16
|
Gregório H, Raposo T, Queiroga FL, Pires I, Pena L, Prada J. High COX-2 expression in canine mast cell tumours is associated with proliferation, angiogenesis and decreased overall survival. Vet Comp Oncol 2016; 15:1382-1392. [PMID: 28467670 DOI: 10.1111/vco.12280] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2016] [Revised: 09/30/2016] [Accepted: 10/02/2016] [Indexed: 12/23/2022]
Abstract
COX-2 overexpression is associated with several hallmarks of carcinogenesis such as proliferation, angiogenesis, invasion and metastasis. Fifty cases of canine mast cell tumours (MCT) were retrospectively evaluated and submitted to immunohistochemistry for COX-2, CD31, Ki-67, MAC-387 and CD3. Furthermore its relationship with clinicopathological variables and overall survival (OS) was analysed. COX-2 intensity (P = 0.016), but not COX-2 extension nor score was associated with decreased OS and higher grades of malignancy according to Patnaik (P = 0.002) and Kiupel (P < 0.001) grading systems. Cox-2 intensity was also associated with higher Ki-67 scores (P = 0.009), higher mitotic index (P = 0.022) and higher microvascularization density (P = 0.045). No association was observed for COX-2 intensity and CD3-T lymphocyte (P = 0.377) and macrophage infiltration (P = 0.261) by MAC-387 immunollabelling, suggesting an active role of COX-2 in MCT oncogenesis mainly through proliferation and angiogenesis stimulation making it a potentially clinical relevant prognosis marker and therapeutic target.
Collapse
Affiliation(s)
- H Gregório
- CHV, Centro Hospitalar Veterinário, Porto, Portugal.,Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal
| | - T Raposo
- Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, UK
| | - F L Queiroga
- Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.,Center for Technology of Agro-Environment and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.,Center for the Study of Animal Sciences, CECA-ICETA, University of Porto, Porto, Portugal
| | - I Pires
- Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.,CECAV, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal
| | - L Pena
- Department of Veterinary Medicine and Science, University Complutense of Madrid, Veterinary School Hospital, Madrid, Spain
| | - J Prada
- Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.,CECAV, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal
| |
Collapse
|
17
|
Serra Varela JC, Pecceu E, Handel I, Lawrence J. Tolerability of a rapid-escalation vinblastine-prednisolone protocol in dogs with mast cell tumours. Vet Med Sci 2016; 2:266-280. [PMID: 29067202 PMCID: PMC5645846 DOI: 10.1002/vms3.42] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2015] [Revised: 06/10/2016] [Accepted: 06/23/2016] [Indexed: 12/21/2022] Open
Abstract
Optimal chemotherapy protocols for high-risk mast cell tumours (MCTs) are unknown. The purpose of this study was to determine the tolerability and toxicity profile of a rapidly escalating vinblastine and prednisolone protocol (VPP) in which 3.00 mg/m2 was administered once 7 days apart: at day 14 and at day 21. Dogs with chemotherapy-naïve MCTs presenting to the Oncology Service of a single institution were prospectively enrolled to receive escalating vinblastine, and haematology and a standardised quality-of-life questionnaire were assessed prior to each dosage. Thirty-four dogs were included: 30 with microscopic disease treated with adequate local therapy and four with macroscopic disease. Of 220 doses of vinblastine administered, 4% were associated with grade 3 and 4 toxicity. A total of 70% of dogs tolerated 3.00 mg/m2 given 7 days apart at day 14 and 21, although 29% of dogs developed dose-limiting toxicities and 8% discontinued the protocol due to toxicity. In conclusion, VPP was well-tolerated overall, although prior to further dose intensity optimisation, it is important to determine if dose intensity is linked to outcome in canine MCT to avoid unwarranted toxicity.
Collapse
Affiliation(s)
- Juan Carlos Serra Varela
- Small Animal Hospital of The University of Edinburgh, Royal (Dick) School of Veterinary StudiesEaster Bush CampusEdinburghEH25 9REUK
| | - Evi Pecceu
- Small Animal Hospital of The University of Edinburgh, Royal (Dick) School of Veterinary StudiesEaster Bush CampusEdinburghEH25 9REUK
| | - Ian Handel
- Small Animal Hospital of The University of Edinburgh, Royal (Dick) School of Veterinary StudiesEaster Bush CampusEdinburghEH25 9REUK
| | - Jessica Lawrence
- Small Animal Hospital of The University of Edinburgh, Royal (Dick) School of Veterinary StudiesEaster Bush CampusEdinburghEH25 9REUK
| |
Collapse
|
18
|
van Lelyveld S, Warland J, Miller R, Maw H, Foale R, Goodfellow M, Dobson J. Comparison between Ki-67 index and mitotic index for predicting outcome in canine mast cell tumours. J Small Anim Pract 2015; 56:312-9. [DOI: 10.1111/jsap.12320] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Revised: 11/30/2014] [Accepted: 12/01/2014] [Indexed: 01/07/2023]
Affiliation(s)
- S. van Lelyveld
- Dovecote Veterinary Hospital; 5 Delven Lane, Derby Castle Donington Derby DE74 2LJ
- Davies Veterinary Specialists, Manor Farm Business Park; Higham Gobion, Hitchin Hertfordshire SG5 3HR
| | - J. Warland
- Department of Veterinary Medicine; University of Cambridge; Cambridge CB3 OES
| | - R. Miller
- Dick White Referrals, Station Farm; Six Mile Bottom Cambridgeshire CB8 0UH
| | - H. Maw
- Department of Veterinary Medicine; University of Cambridge; Cambridge CB3 OES
| | - R. Foale
- Dick White Referrals, Station Farm; Six Mile Bottom Cambridgeshire CB8 0UH
| | - M. Goodfellow
- Davies Veterinary Specialists, Manor Farm Business Park; Higham Gobion, Hitchin Hertfordshire SG5 3HR
| | - J. Dobson
- Department of Veterinary Medicine; University of Cambridge; Cambridge CB3 OES
| |
Collapse
|
19
|
Weishaar K, Thamm D, Worley D, Kamstock D. Correlation of Nodal Mast Cells with Clinical Outcome in Dogs with Mast Cell Tumour and a Proposed Classification System for the Evaluation of Node Metastasis. J Comp Pathol 2014; 151:329-38. [DOI: 10.1016/j.jcpa.2014.07.004] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2014] [Revised: 07/02/2014] [Accepted: 07/11/2014] [Indexed: 11/16/2022]
|
20
|
Garrett LD. Canine mast cell tumors: diagnosis, treatment, and prognosis. VETERINARY MEDICINE-RESEARCH AND REPORTS 2014; 5:49-58. [PMID: 32670846 PMCID: PMC7337164 DOI: 10.2147/vmrr.s41005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Accepted: 04/23/2014] [Indexed: 11/25/2022]
Abstract
Mast cell tumors (MCTs) are the most common malignant skin cancer in dogs, and significant variability exists in their biological behavior. Most MCTs are cured with appropriate local therapy, but a subset shows malignant behavior with the potential to spread to lymph nodes, liver, spleen, and other areas and to thus become a systemic cancer. Because of this variable behavior, it is difficult to predict how any individual tumor is going to behave. The variability thus creates uncertainty in deciding what a particular dog’s prognosis is, whether staging tests to assess for metastasis are needed, and even what treatments will be necessary for best outcome. In addition to controversies over the potential for development of systemic disease, or diffuse metastasis, controversies also exist over what treatment is needed to best attain local control of these tumors. This article will briefly discuss the diagnosis of MCTs in dogs and will summarize the literature in regards to the controversial topics surrounding the more aggressive form of this disease, with recommendations made based on published studies.
Collapse
Affiliation(s)
- Laura D Garrett
- Department of Veterinary Clinical Medicine, University of Illinois College of Veterinary Medicine, Urbana, IL, USA
| |
Collapse
|
21
|
Lejeune A, Skorupski K, Frazier S, Vanhaezebrouck I, Rebhun RB, Reilly CM, Rodriguez CO. Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012). Vet Comp Oncol 2013; 13:267-80. [PMID: 23721492 DOI: 10.1111/vco.12042] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2012] [Revised: 04/24/2013] [Accepted: 04/29/2013] [Indexed: 11/28/2022]
Abstract
This retrospective case series evaluates the outcome of 21 dogs with grade II stage 2 mast cell tumour (MCT) treated with adequate local therapy and adjuvant systemic chemotherapy (prednisone, vinblastine and CCNU). The median survival for all dogs was 1359 days (range, 188-2340). Median disease-free interval was 2120 days (149-2325 days). Dogs treated with surgery and chemotherapy had shorter survival (median, 1103 days; 188-2010 days) than those that underwent surgery, radiation therapy and chemotherapy as part of their treatment (median, 2056 days; 300-2340 days). Two patients had local recurrence in the radiation field and four patients had de novo MCT. Distant metastasis was not observed in any dogs. The results of this study suggest that, in the presence of loco-regional lymph node metastasis in grade II MCT, the use of prednisone, vinblastine and CCNU after adequate local-regional therapy can provide a median survival in excess of 40 months.
Collapse
Affiliation(s)
- A Lejeune
- Davis William R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis, CA, USA
| | - K Skorupski
- Davis William R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis, CA, USA.,Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, CA, USA
| | - S Frazier
- Davis William R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis, CA, USA.,Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, CA, USA.,Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA
| | - I Vanhaezebrouck
- Davis William R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis, CA, USA.,Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA
| | - R B Rebhun
- Davis William R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis, CA, USA.,Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, CA, USA
| | - C M Reilly
- Davis William R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis, CA, USA.,Department of Veterinary Pathology, Microbiology and Immunology, University of California, Davis, CA, USA
| | - C O Rodriguez
- Davis William R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis, CA, USA.,Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, CA, USA
| |
Collapse
|
22
|
Worley DR. Incorporation of sentinel lymph node mapping in dogs with mast cell tumours: 20 consecutive procedures. Vet Comp Oncol 2012; 12:215-26. [DOI: 10.1111/j.1476-5829.2012.00354.x] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2011] [Revised: 08/06/2012] [Accepted: 08/07/2012] [Indexed: 12/21/2022]
Affiliation(s)
- Deanna R. Worley
- Department of Clinical Sciences, Flint Animal Cancer Center; Colorado State University; Fort Collins CO USA
| |
Collapse
|
23
|
Bernstein JA, Storey ES, Bauer RW. Moh’s micrographic surgery for the management of a periocular mast cell tumor in a dog. Vet Ophthalmol 2012; 16:234-9. [DOI: 10.1111/j.1463-5224.2012.01059.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Blackwood L, Murphy S, Buracco P, De Vos JP, De Fornel-Thibaud P, Hirschberger J, Kessler M, Pastor J, Ponce F, Savary-Bataille K, Argyle DJ. European consensus document on mast cell tumours in dogs and cats. Vet Comp Oncol 2012; 10:e1-e29. [DOI: 10.1111/j.1476-5829.2012.00341.x] [Citation(s) in RCA: 134] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- L. Blackwood
- Small Animal Teaching Hospital, The Leahurst Campus; University of Liverpool Chester High Road; Neston Wirral CH64 7TE UK
| | - S. Murphy
- The Animal Health Trust; Suffolk CB8 7UU UK
| | - P. Buracco
- Department of Animal Pathology, School of Veterinary Medicine; University of Turin; Grugliasco (TO) Italy
| | - J. P. De Vos
- “De Ottenhorst” Veterinary Oncology Referral Centre; Terneuzen The Netherlands
| | - P. De Fornel-Thibaud
- DESV Internal Medicine, Centre de Cancérologie Vétérinaire; Maisons-Alfort France
| | - J. Hirschberger
- Medizinische Kleintierklinik Clinic for Small Animal Medicine, Center for Clinical Veterinary Medicine; Ludwig-Maximilians-Universität München Veterinärstr; München Germany
| | | | - J. Pastor
- Patología Médica Facultad de Veterinaria; Universidad Autónoma de Barcelona; Bellaterra Spain
| | - F. Ponce
- VetAgro Sup; Université Lyon 1; Lyon France
| | | | - D. J. Argyle
- Royal (Dick) School of Veterinary Studies and Roslin Institute; Easter Bush Midlothian EH25 9RG UK
| |
Collapse
|
25
|
Mackowiak II, Gentile LB, Chaible LM, Nagamine MK, Guerra JM, Mota EFF, Matera JM, Mennecier G, Sanches DS, Dagli MLZ. E-cadherin in canine mast cell tumors: decreased expression and altered subcellular localization in Grade 3 tumors. Vet J 2012; 194:405-11. [PMID: 22766308 DOI: 10.1016/j.tvjl.2012.05.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2011] [Revised: 05/18/2012] [Accepted: 05/19/2012] [Indexed: 11/19/2022]
Abstract
Mast cell tumors (MCTs) are the most frequent round cell tumors in dogs and comprise approximately 21% of all canine cutaneous tumors. MCTs are highly invasive and metastatic corresponding to the histological grade. E-cadherin is an adhesion molecule expressed in epithelial cells and although it is an epithelial cellular marker, studies have shown expression of E-cadherin in canine round cell tumors. To better characterize the expression pattern of E-cadherin in several different histological grades of MCTs in dogs, the expression and localization of the adhesion molecule was investigated using immunohistochemistry. For this purpose, 18 cutaneous MCTs were classified into three histological grades, 1, 2 or 3. Clinical history and follow-up data were available for all of the dogs. Cytoplasmic and nuclear expressions of E-cadherin in all three types of tumors were verified by immunostaining using two different antibodies. There was decreased E-cadherin expression in the more aggressive MCTs (Grade 3), suggesting an association between E-cadherin and tumor aggressiveness. Additionally, the loss of E-cadherin expression in either the cytoplasm or nucleus in more aggressive and undifferentiated tumor types confirmed the importance of cellular adhesion in tumor behavior.
Collapse
Affiliation(s)
- I I Mackowiak
- Laboratory of Experimental and Comparative Oncology, Department of Pathology, School of Veterinary Medicine and Animal Science of the University of São Paulo, São Paulo, Brazil
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Burrow RD, Gregory SP, Giejda AA, White RN. Penile amputation and scrotal urethrostomy in 18 dogs. Vet Rec 2011; 169:657. [DOI: 10.1136/vr.100039] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- R. D. Burrow
- The Royal Veterinary College; University of London; London UK
| | - S. P. Gregory
- Department of Veterinary Clinical Sciences; Royal Veterinary College; North Mymms Hertfordshire AL9 7TA UK
| | - A. A. Giejda
- The Royal Veterinary College; University of London; London UK
| | - R. N. White
- Willows Veterinary Centre and Referral Service; Shirley Solihull West Midlands B90 4NH UK
| |
Collapse
|
27
|
O'Connell K, Thomson M. Evaluation of prognostic indicators in dogs with multiple, simultaneously occurring cutaneous mast cell tumours: 63 cases. Vet Comp Oncol 2011; 11:51-62. [DOI: 10.1111/j.1476-5829.2011.00301.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Berlato D, Stewart J, Newton R, Maglennon GA, Monti P, Flindall A, Murphy S. Evaluation of minichromosome maintenance protein 7 as a prognostic marker in canine cutaneous mast cell tumours*. Vet Comp Oncol 2011; 10:135-42. [DOI: 10.1111/j.1476-5829.2011.00287.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
29
|
Schultheiss PC, Gardiner DW, Rao S, Olea-Popelka F, Tuohy JL. Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 2011; 238:1464-9. [DOI: 10.2460/javma.238.11.1464] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
30
|
Fife M, Blocker T, Fife T, Dubielzig RR, Dunn K. Canine conjunctival mast cell tumors: a retrospective study. Vet Ophthalmol 2011; 14:153-60. [DOI: 10.1111/j.1463-5224.2010.00857.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
McNiel EA, Prink AL, O'Brien TD. Evaluation of risk and clinical outcome of mast cell tumours in pug dogs. Vet Comp Oncol 2009; 4:2-8. [PMID: 19754824 DOI: 10.1111/j.1476-5810.2006.00085.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Mast cell tumours (MCT) are common in dogs and characterized by diverse biologic behaviour. Our objective was to evaluate the risk of MCT in pugs and to describe the clinical behaviour of MCT in this breed. Data obtained from the Veterinary Medicine Database demonstrate significantly increased frequency of MCT in pugs compared with other dogs (OR = 2.28, 95% CI = 1.81-2.86). The medical records for 25 purebred pugs with a histologic diagnosis of MCT were reviewed. Multiple cutaneous tumours were documented in 14 (56 %) of the dogs. Histologic review of 64 tumours from these dogs confirmed that most tumours (94%) were low to intermediate grade. Sixty-four per cent of these dogs are still living, while only three dogs (12%) have died due to mast cell disease. A median survival time has not been reached. The median follow-up time is 660 days from the diagnosis of the first MCT. We conclude that MCT in pugs are relatively benign, despite the presence of multiple cutaneous tumours in most cases. Multiple tumours in breeds with predisposition to MCT may indicate separate primaries rather than advanced stage disease.
Collapse
Affiliation(s)
- E A McNiel
- Departments of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, Saint Paul, MN 55108, USA.
| | | | | |
Collapse
|
32
|
Krick EL, Billings AP, Shofer FS, Watanabe S, Sorenmo KU. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival*. Vet Comp Oncol 2009; 7:130-8. [DOI: 10.1111/j.1476-5829.2009.00185.x] [Citation(s) in RCA: 79] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Welle MM, Bley CR, Howard J, Rüfenacht S. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Vet Dermatol 2009; 19:321-39. [PMID: 18980632 DOI: 10.1111/j.1365-3164.2008.00694.x] [Citation(s) in RCA: 121] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Mast cells (MCs) are well known for their neoplastic transformation in solitary and multiple cutaneous mast cell tumours (MCTs), as well as visceral and systemic mastocytosis. Dogs have a unique risk of developing cutaneous MCTs, and they account for 7% to 21% of all canine skin tumours. The aetiology of canine MCTs is unknown but is probably multifactorial. This article reviews up-to-date knowledge on the pathogenesis, the clinical presentation, the clinical prognostic factors, the diagnostic workup including clinical staging, cytological findings, histological findings and the various grading systems which have been evaluated based on morphology, the assessment of proliferation markers and other factors such as vessel density. Furthermore, detailed information about current treatment protocols for canine cutaneous MCTs is provided.
Collapse
Affiliation(s)
- Monika M Welle
- Institute of Animal Pathology, Vetsuisse Faculty and University of Berne, Berne, Switzerland.
| | | | | | | |
Collapse
|
34
|
Marconato L, Marchetti V, Francione D, Masserdotti C, Gregori M, Leotta R, Abramo F. Morphometrical approach for predicting regional lymph node micrometastatic load in canine mast cell tumours: preliminary results. Vet Comp Oncol 2008; 6:162-70. [DOI: 10.1111/j.1476-5829.2008.00157.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Hadzijusufovic E, Rebuzzi L, Gleixner KV, Ferenc V, Peter B, Kondo R, Gruze A, Kneidinger M, Krauth MT, Mayerhofer M, Samorapoompichit P, Greish K, Iyer AK, Pickl WF, Maeda H, Willmann M, Valent P. Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. Exp Hematol 2008; 36:1461-70. [PMID: 18723263 DOI: 10.1016/j.exphem.2008.06.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2007] [Revised: 06/02/2008] [Accepted: 06/03/2008] [Indexed: 11/25/2022]
Abstract
OBJECTIVE Advanced mast cell (MC) neoplasms are usually resistant to conventional therapy. Therefore, current research focuses on new targets in neoplastic MC and development of respective targeted drugs. Mastocytomas in dogs often behave as aggressive tumors. We report that heat-shock protein 32 (Hsp32), also known as heme oxygenase-1, is a survival-enhancing molecule and new target in canine mastocytoma cells. MATERIALS AND METHODS As assessed by reverse transcriptase polymerase chain reaction, Northern blotting, immunocytochemistry, and Western blotting, primary neoplastic dog MC, and the canine mastocytoma-derived cell line C2 expressed Hsp32 mRNA and the Hsp32 protein in a constitutive manner. RESULTS The KIT-targeting drug midostaurin inhibited expression of Hsp32, as well as survival in C2 cells. Confirming the functional role of Hsp32, the inhibitory effect of midostaurin on C2 cells was markedly reduced by the Hsp32-inductor hemin. Two pharmacologic Hsp32-inhibitors, styrene maleic-acid micelle-encapsulated ZnPP (SMA-ZnPP) and pegylated zinc-protoporphyrin (PEG-ZnPP) were applied. Both drugs were found to inhibit proliferation of C2 cells as well as growth of primary neoplastic canine MC. The growth-inhibitory effects of SMA-ZnPP and PEG-ZnPP were dose- and time-dependent (IC(50): 1-10 muM) and found to be associated with induction of apoptosis. CONCLUSIONS Hsp32 is an important survival factor and interesting new target in neoplastic canine MC. Trials with Hsp32-targeted drugs are now warranted to define the clinical efficacy of these drugs.
Collapse
Affiliation(s)
- Emir Hadzijusufovic
- Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Stanclift RM, Gilson SD. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 2008; 232:53-62. [DOI: 10.2460/javma.232.1.53] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
37
|
Romansik EM, Reilly CM, Kass PH, Moore PF, London CA. Mitotic index is predictive for survival for canine cutaneous mast cell tumors. Vet Pathol 2007; 44:335-41. [PMID: 17491075 DOI: 10.1354/vp.44-3-335] [Citation(s) in RCA: 124] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Mitotic index (MI) is an indirect measure of cell proliferation that has been demonstrated to be a strong predictor of outcome for several human and canine cancers. The purpose of this study was to evaluate the utility of MI as a predictor of biologic behavior and survival in dogs with cutaneous mast cell tumors (MCTs). Medical records from 148 dogs with histologically confirmed MCTs were reviewed. Information regarding tumor grade, local recurrence, metastatic disease, date of death/last follow-up, and outcome was obtained. The region of the tumor with the highest overall mitotic activity was chosen for evaluation, and the MI value was defined as the number of mitotic figures/10 high-power fields (400x, 2.7 mm(2)). A Cox proportional hazards regression model was used to compare MI with survival data. A Mann-Whitney test was used to compare MI on the basis of the development of local recurrence and metastatic disease. The MI correlated directly with tumor grade (P < .0001). The median survival time for dogs with an MI < or =5 was significantly longer (70 months) than for those with an MI >5 (2 months), regardless of grade (P < .001). For grade II tumors with an MI < or =5, the median survival time (MST) was 70 months, compared with 5 months for those with an MI >5 (P < .001). For grade III tumors with an MI < or =5, the MST was not reached, compared with <2 months for those with an MI >5 (P < .001). In conclusion, MI is a strong predictor of overall survival for dogs with cutaneous MCTs and should be included as a prognostic indicator when determining therapeutic options.
Collapse
Affiliation(s)
- E M Romansik
- Veterinary Medical Teaching Hospital, UC Davis, CA, USA
| | | | | | | | | |
Collapse
|
38
|
OZAKI K, YAMAGAMI T, NOMURA K, NARAMA I. Prognostic Significance of Surgical Margin, Ki-67 and Cyclin D1 Protein Expression in Grade II Canine Cutaneous Mast Cell Tumor. J Vet Med Sci 2007; 69:1117-21. [DOI: 10.1292/jvms.69.1117] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
- Kiyokazu OZAKI
- Department of Pathology, Faculty of Pharmaceutical Science, Setsunan University
| | | | | | - Isao NARAMA
- Department of Pathology, Faculty of Pharmaceutical Science, Setsunan University
| |
Collapse
|
39
|
Rebuzzi L, Willmann M, Sonneck K, Gleixner KV, Florian S, Kondo R, Mayerhofer M, Vales A, Gruze A, Pickl WF, Thalhammer JG, Valent P. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol 2006; 115:320-33. [PMID: 17196258 DOI: 10.1016/j.vetimm.2006.11.009] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2006] [Revised: 10/27/2006] [Accepted: 11/06/2006] [Indexed: 10/23/2022]
Abstract
Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis and a potential autocrine growth factor for neoplastic cells in various malignancies. In the present study, we have investigated expression of VEGF and VEGF receptors in canine mastocytomas and the canine mastocytoma cell line C2. As assessed by immunostaining of tissue sections and cytospin slides, primary neoplastic mast cells (MC) and C2 cells were found to express the VEGF protein. In Northern blot and RT-PCR experiments, C2 cells expressed VEGF mRNA in a constitutive manner. VEGF mRNA expression in C2 cells was counteracted by LY294002 and rapamycin, suggesting involvement of the PI3-kinase/mTOR pathway. Moreover, C2 cells were found to express VEGF receptor-1 (Flt-1) and VEGF receptor-2 (KDR). However, recombinant VEGF failed to promote (3)H-thymidine uptake in C2 cells, and a neutralizing anti-VEGF antibody (bevacizumab) failed to downregulate spontaneous proliferation in these cells. In addition, rapamycin decreased the expression of VEGF in C2 cells at the mRNA and protein level without suppressing their proliferation. Together, canine mastocytoma cells express VEGF as well as VEGF receptors. However, despite co-expression of VEGF and its receptors, VEGF is not utilized as an autocrine growth regulator by canine mastocytoma cells.
Collapse
Affiliation(s)
- Laura Rebuzzi
- Department for Small Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Sfiligoi G, Rassnick KM, Scarlett JM, Northrup NC, Gieger TL. Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990?2001). J Am Vet Med Assoc 2005; 226:1368-74. [PMID: 15844431 DOI: 10.2460/javma.2005.226.1368] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To compare clinical outcome of dogs with cutaneous mast cell tumors (MCTs) in the inguinal or perineal region with outcome for dogs with MCTs in other cutaneous locations. DESIGN Retrospective study. ANIMALS 37 dogs with MCTs in the inguinal or perineal region and 87 dogs with MCTs in other cutaneous locations. PROCEDURE Information obtained from the medical records included sex, breed, age, histologic grade of all tumors, number and location of all tumors, tumor size (ie, diameter of the tumor), completeness of surgical excision, treatments administered in addition to surgery, and outcome. In all dogs, the primary treatment consisted of surgical excision. RESULTS Disease-free interval and survival time for dogs with MCTs in the inguinal or perineal region were not significantly different from values for dogs with MCTs in other cutaneous locations. Dogs with incompletely excised tumors, dogs with grade III tumors, and dogs that received systemic treatment were 2, 2.5, and 4 times as likely, respectively, to have a relapse. Factors significantly associated with a shorter survival time were age > 8 years, metastatic disease at the time of initial diagnosis, and tumor relapse. CONCLUSIONS AND CLINICAL RELEVANCE Results of the present study suggest that dogs with MCTs in the inguinal or perineal region do not have a worse prognosis in regard to disease-free interval or survival time than do dogs with MCTs in other cutaneous locations. Treatment recommendations for dogs with cutaneous MCTs should be based on confirmed predictors of biological behavior, such as histologic grade and clinical stage.
Collapse
Affiliation(s)
- Gabriella Sfiligoi
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
| | | | | | | | | |
Collapse
|